



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

## NOTICE OF ALLOWANCE AND FEE(S) DUE

21839 7590 03/17/2006

BUCHANAN INGERSOLL PC  
(INCLUDING BURNS, DOANE, SWECKER & MATHIS)  
POST OFFICE BOX 1404  
ALEXANDRIA, VA 22313-1404



EXAMINER	
GUPTA, ANISH	
ART UNIT	PAPER NUMBER
1654	
DATE MAILED: 03/17/2006	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/773,229	02/09/2004	Ronald Mathison	024916-013	4016
TITLE OF INVENTION: PEPTIDES FOR TREATMENT OF INFLAMMATION AND SHOCK				

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$700	\$300	\$1000	06/19/2006

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. **PROSECUTION ON THE MERITS IS CLOSED.** THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN **THREE MONTHS** FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. **THIS STATUTORY PERIOD CANNOT BE EXTENDED.** SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

### HOW TO REPLY TO THIS NOTICE:

#### I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.
- B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

**IMPORTANT REMINDER:** Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

# **PART B - FEE(S) TRANSMITTAL**

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
or Fax (571)-273-2885**

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

21839 7590 03/17/2006

**BUCHANAN INGERSOLL PC  
(INCLUDING BURNS, DOANE, SWECKER & MATHIS)  
POST OFFICE BOX 1404  
ALEXANDRIA, VA 22313-1404**

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

## **Certificate of Mailing or Transmission**

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/773,229	02/09/2004	Ronald Mathison	024916-013	4016

TITLE OF INVENTION: PEPTIDES FOR TREATMENT OF INFLAMMATION AND SHOCK

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$700	\$300	\$1000	06/19/2006

EXAMINER	ART UNIT	CLASS-SUBCLASS
GUPTA, ANISH	1654	514-002000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  
☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list  
 (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, 1 \_\_\_\_\_  
 (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 \_\_\_\_\_  
 3 \_\_\_\_\_

## **3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)**

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

## **4a. The following fee(s) are enclosed:**

- ☐ Issue Fee  
☐ Publication Fee (No small entity discount permitted)  
☐ Advance Order - # of Copies \_\_\_\_\_

## **4b. Payment of Fee(s):**

- ☐ A check in the amount of the fee(s) is enclosed.  
☐ Payment by credit card. Form PTO-2038 is attached.  
☐ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number \_\_\_\_\_ (enclose an extra copy of this form).

## **5. Change in Entity Status (from status indicated above)**

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature \_\_\_\_\_

Date \_\_\_\_\_

Typed or printed name \_\_\_\_\_

Registration No. \_\_\_\_\_

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/773,229	02/09/2004	Ronald Mathison	024916-013	4016
21839	7590	03/17/2006	EXAMINER	
BUCHANAN INGERSOLL PC (INCLUDING BURNS, DOANE, SWECKER & MATHIS) POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			GUPTA, ANISH	
			ART UNIT	PAPER NUMBER
			1654	
			DATE MAILED: 03/17/2006	

## Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/773,229	MATHISON ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Anish Gupta	1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 2-28-06.
2. ☒ The allowed claim(s) is/are 21-, 23-32, 34-50.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☒ All    b) ☐ Some\*    c) ☐ None    of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☒ Certified copies of the priority documents have been received in Application No. 09/051,395
    3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.


Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
  - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
    - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
  - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

- |  |  |
|--|--|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892)   | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 6. <input type="checkbox"/> Interview Summary (PTO-413),<br>Paper No./Mail Date _____. |
| 3. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),<br>Paper No./Mail Date <u>2-9-04</u> | 7. <input type="checkbox"/> Examiner's Amendment/Comment                               |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br>of Biological Material                             | 8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance              |
|  | 9. <input type="checkbox"/> Other _____.   |

  
**ANISH GUPTA**  
 PRIMARY EXAMINER

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 024916-013	APPLICATION NO. Not Yet Assigned
	APPLICANT Ronald MATHISON et al.	
	FILING DATE February 9, 2004	GROUP Not Yet Assigned
	<b>FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
DA	4,880,779		GALLAHER	11-14-1989

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No	
DA	WO 92/11858		PCT	07-23-1992		

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DA	MATHISON et al., "Neural regulation of neutrophil involvement in pulmonary inflammation," <i>Comp. Physiol.</i> , 1993, pp. 39-48, vol. 106C, no. 1, Springer-Verlag Heidelberg, Heidelberg, Germany.
	Bachem Feinchemikalien AG, Hauptstrasse 144, CH-4416 Bubendorf/Switzerland, <i>Bachem Catalog S13</i> , 1993, pages 203 and 522, Abstract No. XP002051006.
	ABDERHALDEN et al., "Ubr das Verhalten von Tetrapeptiden gegenüber Erepsin und Trypsin, an deren Aufbau Glykokoll (2 Mol), 1(+)- Alanin (1 Mol) und 1(-)-Tyrosin (1 Mol) beteiligt sind", <i>Fermentforschung</i> , 1942, pps. 98-114, vol. 16.
	SLOOTSTRA, "Structural aspects of antibody-antigen interaction revealed through small random peptide libraries", <i>Molecular Diversity</i> , 1996, pp. 87-96, vol. 1, Kluwer Academic Publishers, Basel, Switzerland.
	MATHISON et al., "Submandibular glands: novel structures ...", <i>Can. J. of Physiol. Pharmacol.</i> , 1997, pp. 407-413, vol. 75, Abstract No. XP992051009, National Research Council of Canada, Ottawa, Ontario, Canada.
	GRANT, "Synthetic Peptides: A User's Guide," Freeman & Company, 1992, page 53.
	WILKES et al., "Critical Ionizing Groups in Aeromonas Neutral Protease," <i>J. Biol. Chem.</i> , 1988, pp. 1821-1825, vol. 263, no. 4, Walter de Gruyter, Berlin, Germany.
	MATHISON et al., "Temporal analysis of the anti-inflammatory effects of decentralization of the superior cervical ganglia," <i>American Journal of Physiol.</i> , 1994, pp. R1537-43, vol. 266, American Physiological Society, Bethesda, MD.
	MATHISON et al., "Removal of the submandibular glands increases the acute hypotensive response to endotoxin," <i>Circulatory Shock</i> , 1993, pp 52-58, vol. 39, Wiley-Liss, Inc., New York, New York.
DA	NGO et al., "Computational Complexity, Potein Structure Prediction, and the Levinthal Paradox, The Protein Folding Problem and Tertiary Structure Prediction, 1994, <i>Ed. K. Merz and L. Le Grand</i> , BirkHauser, Boston, MA, pp. 491-495.

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 024916-013	APPLICATION NO. Not Yet Assigned
	APPLICANT Ronald MATHISON et al.	
	FILING DATE February 9, 2004	GROUP Not Yet Assigned
	<b>FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ag	RUDINGER, "Characteristics of the amino acids as components of a peptide hormone sequence," <u>Peptide Hormones</u> , Ed. J.A. Parsons, National Institute for Medical Research, Mill Hill, London, University Park Press, Baltimore, MD, pp. 1-7, 1976.
	BARKA, "Biologically Active Polypeptides in Submandibular Glands," <i>The Journal of Histochemistry and Cytochemistry</i> , 1980, pp. 836-859, vol. 28, no. 8, The Histochemical Society/High Wire Press, New York, New York.
	BOYER et al., "Une fonction non exocrine de la glande sous-maxillaire," <i>Annales d'Endocrinologie</i> , 1991, pp. 307-322, vol. 52, Paris, France.
	MATHISON et al., "Neuroendocrine regulation of inflammation and tissue repair by submandibular gland factors," <i>Immunology Today</i> , 1994, pp. 527-531, vol. 15, no. 11, Elsevier Science, Ltd., England.
	EPSTEIN et al., "The role of saliva in oral health and the causes and effects of xerostomia," <i>The Canadian Dental Association Journal</i> , 1992, pp. 217-221, vol. 58.
	KINGSNORTH et al., "Epidermal growth factor increases tensile strength in intestinal wounds in pigs," <i>Br. J. Surg.</i> , 1990, pp. 409-412, vol. 77, John Wiley & Sons, Inc., Chichester, England & NY.
	SKINNER et al., "Influence of Desalivation on Acid Secretory Output and Gastric Mucosal Integrity in the Rat," <i>Gastroenterology</i> , 1981, pp. 335-339, vol. 81, no. 2, WB Saunders, Philadelphia, PA.
	GRAY et al., "Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar lined oesophagus," <i>Br. J. Surg.</i> , 1991, pp. 1461-1466, vol. 78, John Wiley & Sons, Inc., Chichester, England and New York.
	KURACHI et al., "Evidence for the involvement of the submandibular gland epidermal growth factor in mouse mammary tumorigenesis," <i>Proc. Natl. Acad. USA</i> , 1985, pp. 5940-5943, vol. 82, National Academy of Sciences, Washington, D.C.
	JONES et al., "Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration," <i>Gastrointest. Liver Physiol.</i> , 1995, pp. 872-878, vol. 31, The American Physiological Society, Bethesda, Maryland.
	AMANO et al., "Expression and Localization of Hepatocyte Growth Factor in Rat Submandibular Gland," <i>Growth Factors</i> , 1994, pp. 145-151, vol. 10, Harwood Academic Publishers GmbH, Singapore.
	TSUTSUMI et al., "A physiological Role of Epidermal Growth Factor in male Reproductive Function," <i>Science</i> , 1986, pp. 975-977, vol. 233, Amer. Assn. For the Advancement of Science, Washington, D.C.
ar	TSUTSUMI et al., "The uterine growth-promoting action of epidermal growth factor and its function in the fertility of mice," <i>Journal of Endocrinology</i> , 1993, pp. 437-443, vol. 38, Endocrine Society, Baltimore, MD.

Substitute for forms 1449A/PTO & 1449B/PTO  <b>FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTORNEY'S DKT NO. 024916-013	APPLICATION NO. Not Yet Assigned
	APPLICANT Ronald MATHISON et al.	
	FILING DATE February 9, 2004	GROUP Not Yet Assigned

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
00	ROSINSKI-CHUPIN et al., "The Gene Encoding SMR1, a Precursor-Like Polypeptide of the Male Rat Submaxillary Gland, Has the Same Organization as the Preprothyrotropin-Releasing Hormone Gene," <i>DNA and Cell Biology</i> , 1990, pp. 553-559, vol. 9, no. 8, Mary Ann Liebert, Inc, New York, New York.
	ROSINSKI-CHUPIN et al., "High level of accumulation of a mRNA coding for a precursor-like protein in the submaxillary gland of male rats," <i>Proc. Natl. Acad. USA</i> , 1988, pp. 8553-57, vol. 85, National Academy of Sciences, Washington, D.C.
	KEMP et al., "Suppression and enhancement of <i>in vitro</i> lymphocyte reactivity by factors in rat submandibular gland extracts," <i>Immunology</i> , 1985, pp. 261-67, vol. 56, Elsevier Science, Ltd., England.
	ABDELHALEEM et al., "Identification of immunosuppressive fractions from the rat submandibular salivary gland," <i>Immunology</i> , 1992, pp. 331-37, vol. 76, Elsevier Science, Ltd., England.
	BISSONNETTE et al., "Decentralization of the Superior Cervical Ganglia Inhibits Mast Cell Mediated TNF $\alpha$ -Dependent Cytotoxicity. 1. Potential Role of Salivary Glands," <i>Brain, Behavior, and Immunity</i> , 1993, pp. 293-300, vol. 7, Elsevier, Ltd., England.
	CARTER et al., "Inhibition of neutrophil chemotaxis and activation following decentralization of the superior cervical ganglia," <i>Journal of Leukocyte Biology</i> , 1992, pp. 597-602, vol. 51, Society for Leukocyte Biology, Bethesda, Maryland.
	SAITO et al., "Saliva Inhibits the Chemiluminescence Response, Phagocytosis, and Killing of <i>Staphylococcus epidermidis</i> by Polymorphonuclear Leukocytes," <i>Infection and Immunity</i> , 1988, pp. 2125-32, vol. 56, no. 8, American Society for Microbiology, Washington, D.C.
	RAMASWAMY et al., "Marked Antiinflammatory Effects of Decentralization of the Superior Cervical Ganglia," <i>Journal of Experimental Medicine</i> , 1990, pp. 1819-30, vol. 172, Rockefeller Univ. Press, New York, New York.
00	MATHISON et al., "Role for the Submandibular Gland in Modulating Pulmonary Inflammation following induction of Systemic Anaphylaxis," <i>Brain, Behavior, and Immunity</i> , 1992, pp. 117-129, vol. 6, Elsevier Science, Ltd., London, England.

Examiner Signature		Date Considered	3/14/06
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BEST AVAILABLE COPY

IC1600

PT. 13EN

Organization

Bldg./Room

U. S. DEPARTMENT OF COMMERCE  
COMMISSIONER FOR PATENTS


P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

AN EQUAL OPPORTUNITY EMPLOYER



UNITED STATES POSTAGE  
U.S. OFFICIAL MAIL  
PENALTY FOR  
PRIVATE USE \$300  
PRIMEY BOWES  
02 1A  
0004204479  
MAR 17 2006  
\$ 00.870  
MAILED FROM ZIP CODE 22314